BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dheekollu J, Malecka K, Wiedmer A, Delecluse HJ, Chiang AK, Altieri DC, Messick TE, Lieberman PM. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency. Oncotarget 2017;8:7248-64. [PMID: 28077791 DOI: 10.18632/oncotarget.14540] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Xue WQ, Wang TM, Huang JW, Zhang JB, He YQ, Wu ZY, Liao Y, Yuan LL, Mu J, Jia WH. A comprehensive analysis of genetic diversity of EBV reveals potential high-risk subtypes associated with nasopharyngeal carcinoma in China. Virus Evol 2021;7:veab010. [PMID: 34567789 DOI: 10.1093/ve/veab010] [Reference Citation Analysis]
2 Malecka KA, Dheekollu J, Deakyne JS, Wiedmer A, Ramirez UD, Lieberman PM, Messick TE. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication. J Virol 2019;93:e00487-19. [PMID: 31142669 DOI: 10.1128/JVI.00487-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Zhu QY, Zhao GX, Li Y, Talakatta G, Mai HQ, Le QT, Young LS, Zeng MS. Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. MedComm (2020) 2021;2:175-206. [PMID: 34766141 DOI: 10.1002/mco2.32] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Frappier L. Epstein-Barr virus: Current questions and challenges. Tumour Virus Res 2021;12:200218. [PMID: 34052467 DOI: 10.1016/j.tvr.2021.200218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Soldan SS, Lieberman PM. Epstein-Barr Virus Infection in the Development of Neurological Disorders. Drug Discov Today Dis Models 2020;32:35-52. [PMID: 33897799 DOI: 10.1016/j.ddmod.2020.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893938 DOI: 10.1098/rstb.2016.0271] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 34.0] [Reference Citation Analysis]
7 De Leo A, Calderon A, Lieberman PM. Control of Viral Latency by Episome Maintenance Proteins. Trends Microbiol 2020;28:150-62. [PMID: 31624007 DOI: 10.1016/j.tim.2019.09.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
8 Soldan SS, Anderson EM, Frase DM, Zhang Y, Caruso LB, Wang Y, Deakyne JS, Gewurz BE, Tempera I, Lieberman PM, Messick TE. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein-Barr virus-associated gastric cancer. Gastric Cancer 2021;24:1076-88. [PMID: 33929613 DOI: 10.1007/s10120-021-01193-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhou Y, Xia L, Lin J, Wang H, Oyang L, Tan S, Tian Y, Su M, Wang H, Cao D, Liao Q. Exosomes in Nasopharyngeal Carcinoma. J Cancer 2018;9:767-77. [PMID: 29581754 DOI: 10.7150/jca.22505] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
10 Correia S, Bridges R, Wegner F, Venturini C, Palser A, Middeldorp JM, Cohen JI, Lorenzetti MA, Bassano I, White RE, Kellam P, Breuer J, Farrell PJ. Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases. J Virol 2018;92:e01132-18. [PMID: 30111570 DOI: 10.1128/JVI.01132-18] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
11 Correia S, Palser A, Elgueta Karstegl C, Middeldorp JM, Ramayanti O, Cohen JI, Hildesheim A, Fellner MD, Wiels J, White RE, Kellam P, Farrell PJ. Natural Variation of Epstein-Barr Virus Genes, Proteins, and Primary MicroRNA. J Virol 2017;91:e00375-17. [PMID: 28515295 DOI: 10.1128/JVI.00375-17] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 8.4] [Reference Citation Analysis]
12 Deakyne JS, Malecka KA, Messick TE, Lieberman PM. Structural and Functional Basis for an EBNA1 Hexameric Ring in Epstein-Barr Virus Episome Maintenance. J Virol 2017;91:e01046-17. [PMID: 28701406 DOI: 10.1128/JVI.01046-17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
13 Dominguez RL, Cherry CB, Estevez-Ordonez D, Mera R, Escamilla V, Pawlita M, Waterboer T, Wilson KT, Peek RM, Tavera G, Williams SM, Gulley ML, Emch M, Morgan DR. Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America. BMC Cancer 2019;19:545. [PMID: 31174492 DOI: 10.1186/s12885-019-5726-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Young LS. A novel Epstein-Barr virus subtype associated with nasopharyngeal carcinoma found in South China. Cancer Commun (Lond) 2020;40:60-2. [PMID: 32077639 DOI: 10.1002/cac2.12006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Yu H, Zhang H, Chu Z, Ruan Q, Chen X, Kong D, Huang X, Li H, Tang H, Wu H, Wang Y, Xie W, Ding Y, Yao P. Combination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species. Oncotarget 2017;8:61646-61. [PMID: 28977893 DOI: 10.18632/oncotarget.18661] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
16 Dheekollu J, Wiedmer A, Ayyanathan K, Deakyne JS, Messick TE, Lieberman PM. Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance. Cell 2021;184:643-654.e13. [PMID: 33482082 DOI: 10.1016/j.cell.2020.12.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Messick TE, Smith GR, Soldan SS, McDonnell ME, Deakyne JS, Malecka KA, Tolvinski L, van den Heuvel APJ, Gu BW, Cassel JA, Tran DH, Wassermann BR, Zhang Y, Velvadapu V, Zartler ER, Busson P, Reitz AB, Lieberman PM. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Sci Transl Med 2019;11:eaau5612. [PMID: 30842315 DOI: 10.1126/scitranslmed.aau5612] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
18 Tsang C, Lo K, Nicholls JM, Huang S, Tsao S. Pathogenesis of Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma. Elsevier; 2019. pp. 45-64. [DOI: 10.1016/b978-0-12-814936-2.00003-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Liu L, Yang J, Ji W, Wang C. Curcumin Inhibits Proliferation of Epstein-Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression. Biomed Res Int 2019;2019:8592921. [PMID: 31687403 DOI: 10.1155/2019/8592921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ayee R, Ofori MEO, Wright E, Quaye O. Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans. J Cancer 2020;11:1737-50. [PMID: 32194785 DOI: 10.7150/jca.37282] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
21 Telford M, Hughes DA, Juan D, Stoneking M, Navarro A, Santpere G. Expanding the Geographic Characterisation of Epstein-Barr Virus Variation through Gene-Based Approaches. Microorganisms 2020;8:E1686. [PMID: 33138327 DOI: 10.3390/microorganisms8111686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, Lo KW. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Front Oncol 2020;10:600. [PMID: 32528868 DOI: 10.3389/fonc.2020.00600] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
23 Wang Y, Du S, Zhu C, Wang C, Yu N, Lin Z, Gan J, Guo Y, Huang X, He Y, Robertson E, Qu D, Wei F, Cai Q. STUB1 is targeted by the SUMO-interacting motif of EBNA1 to maintain Epstein-Barr Virus latency. PLoS Pathog 2020;16:e1008447. [PMID: 32176739 DOI: 10.1371/journal.ppat.1008447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kitsou K, Iliopoulou M, Spoulou V, Lagiou P, Magiorkinis G. Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review. Front Oncol 2021;11:687631. [PMID: 34778024 DOI: 10.3389/fonc.2021.687631] [Reference Citation Analysis]
25 Wilson JB, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R. EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. Cancers (Basel) 2018;10:E109. [PMID: 29642420 DOI: 10.3390/cancers10040109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
26 Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. Pathogens 2018;7:E28. [PMID: 29518976 DOI: 10.3390/pathogens7010028] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 14.5] [Reference Citation Analysis]
27 Santiago JC, Goldman JD, Zhao H, Pankow AP, Okuku F, Schmitt MW, Chen LH, Hill CA, Casper C, Phipps WT, Mullins JI. Intra-host changes in Kaposi sarcoma-associated herpesvirus genomes in Ugandan adults with Kaposi sarcoma. PLoS Pathog 2021;17:e1008594. [PMID: 33465147 DOI: 10.1371/journal.ppat.1008594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]